{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:24:14Z","timestamp":1791775454260,"version":"4.3.4"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thromboembolic events remain a major cause of morbidity and mortality in cardiovascular diseases, particularly myocardial infarction, atrial fibrillation (AF), and ischemic stroke. While standard anticoagulants reduce these events, their use is limited by bleeding risks. Asundexian, a Factor XIa inhibitor, has emerged as a potential agent to prevent thrombosis while preserving hemostasis. This meta-analysis evaluates its safety and efficacy across cardiovascular conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review and meta-analysis was registered with PROSPERO (CRD420251039715). Randomized controlled trials (RCTs) comparing Asundexian with placebo or active controls were identified via PubMed, Scopus, and CENTRAL. Outcomes included all-cause mortality, cardiovascular death, ischemic stroke, stroke or systemic embolism, major\/clinically relevant non-major bleeding, and adverse effects. Data were analyzed using a random-effects model; study quality was assessed via Cochrane Risk of Bias Tool 2.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four RCTs were included. The pooled analysis showed no significant difference in all-cause mortality between Asundexian and control (RR 1.04, 95% CI 0.73-1.48,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.83), with low heterogeneity (I\u00b2\u2009=\u200913%). Ischemic stroke rates were also similar (RR 1.64, 95% CI 0.51-5.25,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.40), but with high heterogeneity (I\u00b2\u2009=\u200989%). Cardiovascular-related mortality did not differ between groups (RR 1.13, 95% CI 0.77-1.66,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.53; I\u00b2\u2009=\u20090%). For safety outcomes, ISTH major or clinically relevant non-major bleeding showed a non-significant trend toward lower risk with Asundexian (RR 0.63, 95% CI 0.21-1.91,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.41; I\u00b2\u2009=\u200977%). Stroke or systemic embolism (RR 1.29, 95% CI 0.08-20.70,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.88) and adverse events (RR 1.00, 95% CI 0.95-1.04,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.85) were comparable between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Asundexian demonstrated no significant difference compared to control in all-cause mortality, ischemic stroke, or cardiovascular-related mortality. While there was a non-significant trend toward reduced bleeding risk, no clear benefit was observed for stroke prevention or systemic embolism. The safety profile was comparable, with no increase in adverse events. These findings suggest that Asundexian, at the studied doses, does not provide significant clinical advantages in mortality or thromboembolic outcomes but may have a favorable bleeding profile. Further research is needed to define its potential role in specific high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296251365238","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:25:35Z","timestamp":1753773935000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the Safety and Efficacy of Asundexian in Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1177","volume":"31","author":[{"given":"Zainab","family":"Arif","sequence":"first","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ashbar","family":"Wadood","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sania","family":"Malahat","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmood","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliha","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Adnan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erum","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3283-1982","authenticated-orcid":false,"given":"Aminath","family":"Waafira","sequence":"additional","affiliation":[{"name":"The Maldives National University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306841"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.10.018"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612827666211111150705"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.312012"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.11.051"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04031.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2023-0051"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00795"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.04.021"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15700"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.306925"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020722"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-316977"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.52768\/2833-2725\/1141"},{"key":"e_1_3_2_16_2","article-title":"Differences in pathological composition among large artery occlusion cerebral thrombi, valvular heart disease atrial thrombi and carotid endarterectomy plaques","volume":"11","author":"Liao Y","unstructured":"Liao Y, Guan M, Liang D, et al. Differences in pathological composition among large artery occlusion cerebral thrombi, valvular heart disease atrial thrombi and carotid endarterectomy plaques. Front Neurol [Internet]. 2020 Aug 7 [cited 2024 Apr 12];11.","journal-title":"Front Neurol [Internet]"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs411"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.057"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2018.57804"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15981"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407105"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00456-1"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01588-4"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061612"},{"key":"e_1_3_2_26_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5","author":"Higgins JPT","year":"2024","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5. Cochrane; 2024."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.09.020"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315754"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002819"},{"key":"e_1_3_2_30_2","article-title":"Evolving data on cardiovascular complications in cancer","volume":"213","author":"Willems RAL","unstructured":"Willems RAL, Winckers K, Biesmans C, de Vos-Geelen J, ten Cate H. Evolving data on cardiovascular complications in cancer. Thromb Res. 2022 May 1;213:S87\u2013S94.","journal-title":"Thromb Res"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccep.2020.11.003"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000489"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000312"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.12.004"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1207"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062353"},{"key":"e_1_3_2_37_2","first-page":"576","article-title":"Factor XI inhibitors in early clinical trials: A meta-analysis","volume":"123","author":"Galli M","unstructured":"Galli M, Laborante R, Ortega-Paz L, et al. Factor XI inhibitors in early clinical trials: A meta-analysis. Thromb Haemostasis. 2023 Mar 24;123:576\u2013584.","journal-title":"Thromb Haemostasis"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.03.001"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-316977"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.3085"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251365238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296251365238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251365238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:19Z","timestamp":1777385119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296251365238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":39,"alternative-id":["10.1177\/10760296251365238"],"URL":"https:\/\/doi.org\/10.1177\/10760296251365238","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"article-number":"10760296251365238"}}